Skip to content
★ Sign in to follow
KP

Kathleen P. Bloch

Chief Financial Officer
Total declarations
63
Company
1
▲ Purchases (19 ops.)
€236k
▼ Sales (15 ops.)
€905k

Latest filing published 04 Apr 2024 for Cytosorbents Corp.

Filing timeline

BuySale
Kathleen P. Bloch

Insider track record

Disclosed buys
19
Disclosed sells
15
Signal history

Closed purchases

Market purchases
19
Positive at T+90
18%
Median T+90
-13.4%

Based on 17 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.

Purchases by company

Since each purchase

  • Filed 15 Dec 2023 · 1060 days ago · €46k
    -50.3%
    Entry US$36.60 · Close at T+365 US$18.20
  • Filed 30 May 2023 · 1258 days ago · €2,913
    -70.4%
    Entry US$59.40 · Close at T+365 US$17.60
  • Filed 12 May 2023 · 1276 days ago · €8,658
    -74.8%
    Entry US$66.20 · Close at T+365 US$16.70
  • Filed 06 Jun 2022 · 1617 days ago · €15k
    +29.3%
    Entry US$51.20 · Close at T+365 US$66.20
  • Filed 26 Nov 2021 · 1809 days ago · €18k
    -72.8%
    Entry US$100.80 · Close at T+365 US$27.40

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Kathleen P. Bloch: trading record in brief

This profile gathers the share dealings of Kathleen P. Bloch in Cytosorbents Corp, where the filings describe the role as finance chief. The record holds 63 filings, for trades running from 20 May 2014 to 2 April 2024.

Market trades split into 19 purchases (€236k) and 15 sales (€905k). Netting one side against the other leaves €669k of net selling. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 14 share grants and 15 option exercises.

A typical purchase (the median) is worth €9,977. 3 out of 16 purchases came within 30 days of a purchase by at least one other insider of the same company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. For 17 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 18% of cases, with a median move of -13.4%. These figures describe past trades and do not predict future prices.

On 4 April 2024 came the latest disclosure, a share grant in Cytosorbents Corp. The last purchase on record was published on 15 December 2023, which is 1,060 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.

Companies and markets linked to Kathleen P. Bloch

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations63 total
  • ◆
    Chief Financial OfficerExecutivesCytosorbents Corp
    0SEC
    65,000 shares0Common StockSEC:0001104659-24-043793:0
  • ▲
    Chief Financial OfficerExecutivesCytosorbents Corp
    50,000 USD46SEC
    37,594 shares@ US$1.3348.1% of flowCommon StockSEC:0001104659-23-126427:0
    Canonical exit: 12 Mar 2024 (T+90)
  • ◆
    Chief Financial OfficerExecutivesCytosorbents Corp
    0SEC
    45,000 shares0Common StockSEC:0001104659-23-102316:0
  • ▲
    Interim CFOExecutivesCytosorbents Corp
    3,124 USD25SEC
    1,100 shares@ US$2.840.1% of flowCommon StockSEC:0001104659-23-065680:1
    Canonical exit: 23 Aug 2023 (T+90)
  • ▲
    Interim CFOExecutivesCytosorbents Corp
    3,135 USD25SEC
    1,100 shares@ US$2.850.1% of flowCommon StockSEC:0001104659-23-065680:2
    Canonical exit: 23 Aug 2023 (T+90)
  • ▲
    Interim CFOExecutivesCytosorbents Corp
    3,133 USD23SEC
    1,100 shares@ US$2.84833.0% of flowCommon StockSEC:0001104659-23-065680:0
    Canonical exit: 23 Aug 2023 (T+90)
  • ▲
    Interim CFOExecutivesCytosorbents Corp
    6,260 USD21SEC
    2,000 shares@ US$3.130.3% of flowCommon StockSEC:0001104659-23-059389:1
    Canonical exit: 8 Aug 2023 (T+90)
  • ▲
    Interim CFOExecutivesCytosorbents Corp
    9,510 USD21SEC
    3,000 shares@ US$3.170.4% of flowCommon StockSEC:0001104659-23-059389:2
    Canonical exit: 8 Aug 2023 (T+90)
  • ▲
    Interim CFOExecutivesCytosorbents Corp
    15,298 USD22SEC
    5,000 shares@ US$3.059614.5% of flowCommon StockSEC:0001104659-23-059389:0
    Canonical exit: 8 Aug 2023 (T+90)
  • ◆
    Chief Financial OfficerExecutivesCytosorbents Corp
    0SEC
    55,500 shares0Common StockSEC:0001104659-22-090247:0
  • ▲
    Chief Financial OfficerExecutivesCytosorbents Corp
    16,529 USD41SEC
    8,700 shares@ US$1.899916.0% of flowCommon StockSEC:0001104659-22-068656:0
    Canonical exit: 4 Sept 2022 (T+90)
  • ▲
    Chief Financial OfficerExecutivesCytosorbents Corp
    19,920 USD21SEC
    4,000 shares@ US$4.9818.4% of flowCommon StockSEC:0001104659-21-144035:0
    Canonical exit: 21 Feb 2022 (T+90)
  • ◆
    Chief Financial OfficerExecutivesCytosorbents Corp
    444,556 USD21SEC
    49,450 shares@ US$8.9918.9% of flowCommon StockSEC:0001104659-21-050387:0
  • ◇
    Chief Financial OfficerExecutivesCytosorbents Corp
    43,999 USD19SEC
    7,857 shares@ US$5.601.8% of flowCommon StockSEC:0001104659-21-000337:0
  • ◇
    Chief Financial OfficerExecutivesCytosorbents Corp
    56,000 USD22SEC
    10,000 shares@ US$5.6032.9% of flowCommon StockSEC:0001104659-20-090308:0
  • ◆
    Chief Financial OfficerExecutivesCytosorbents Corp
    0SEC
    43,000 shares0Common StockSEC:0001104659-20-028654:0
  • ▲
    Chief Financial OfficerExecutivesCytosorbents Corp
    11,040 USD37SEC
    3,000 shares@ US$3.681.9% of flowCommon StockSEC:0001104659-19-071352:0
    Canonical exit: 9 Mar 2020 (T+90)
  • ▲
    Chief Financial OfficerExecutivesCytosorbents Corp
    4,270 USD25SEC
    1,000 shares@ US$4.270.7% of flowCommon StockSEC:0001104659-19-067732:0
    Canonical exit: 24 Feb 2020 (T+90)
  • ▲
    Chief Financial OfficerExecutivesCytosorbents Corp
    31,395 USD23SEC
    6,500 shares@ US$4.832.8% of flowCommon StockSEC:0001144204-19-040422:0
    Canonical exit: 14 Nov 2019 (T+90)
  • ▲
    Chief Financial OfficerExecutivesCytosorbents Corp
    8,280 USD21SEC
    1,500 shares@ US$5.520.7% of flowCommon StockSEC:0001144204-19-039650:0
    Canonical exit: 7 Nov 2019 (T+90)
  • ◆
    Chief Financial OfficerExecutivesCytosorbents Corp
    0SEC
    43,000 shares0Common StockSEC:0001144204-19-035843:0
  • ◇
    Chief Financial OfficerExecutivesCytosorbents Corp
    56,000 USD21SEC
    10,000 shares@ US$5.605.0% of flowCommon StockSEC:0001144204-19-030603:0
  • ▲
    Chief Financial OfficerExecutivesCytosorbents Corp
    19,470 USD19SEC
    3,000 shares@ US$6.491.7% of flowCommon StockSEC:0001144204-19-025962:0
    Canonical exit: 8 Aug 2019 (T+90)
  • ◆
    Chief Financial OfficerExecutivesCytosorbents Corp
    0SEC
    4,070 shares0Common StockSEC:0001144204-19-012635:0
  • ◇
    Chief Financial OfficerExecutivesCytosorbents Corp
    28,800 USD19SEC
    10,000 shares@ US$2.881.6% of flowCommon StockSEC:0001144204-18-047336:0

25 of 63 declarations